Clinical Trials Logo

Clinical Trial Summary

This study evaluates patient perceptions around quality of care through telemedicine in neuro-oncology. Studying questionnaires related to perceptions quality of care through telemedicine in patients with brain cancer may help doctors to improve the delivery of care through this modality.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To evaluate the patient-perceived quality of care by group (telemedicine versus in-person visits) in patients with central nervous system (CNS) cancer. SECONDARY OBJECTIVES: I. To characterize the visits provided by telemedicine compared to those in-person. II. To contrast the average time spent on telemedicine visits compared to in-person visits, and the delay between visit order placement and visit occurring. III. To evaluate the domains of patient care addressed on a telemedicine visit versus in-person visit per documentation, including (1) treatment planning, (2) symptom burden, (3) goals of care. IV. To evaluate frequency of acute care sought (through emergency room or urgent care clinic) within 30 days of encounter in telemedicine visit versus (vs) in-person visit. V. The impact of patient and clinical characteristics on perceived quality of care in the context of covariate-adjusted modeling. OUTLINE: Patients complete a survey related to their perceived quality of care via telephone and have their medical chart reviewed prospectively. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04988009
Study type Observational
Source M.D. Anderson Cancer Center
Contact Barbara J O'Brien, MD
Phone 713-794-4380
Email bjobrien@mdanderson.org
Status Recruiting
Phase
Start date August 20, 2020
Completion date December 31, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04062305 - nTMS in Planning Stereotactic Radiosurgery in Patients With Brain Metastases in the Motor Cortex N/A
Recruiting NCT05388877 - E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma Phase 1
Completed NCT03071913 - Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery
Active, not recruiting NCT02595905 - Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Phase 2
Recruiting NCT03270059 - Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System Phase 2
Terminated NCT00096265 - Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer Phase 3
Completed NCT02858869 - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Phase 1
Active, not recruiting NCT04250545 - Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer Phase 1
Recruiting NCT05341349 - Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases Phase 1
Active, not recruiting NCT04114981 - Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease Phase 3
Recruiting NCT03741673 - Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases Phase 3
Completed NCT03680144 - Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases N/A
Completed NCT02167204 - 18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors N/A
Recruiting NCT03750227 - Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors Phase 3
Terminated NCT00659126 - Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors Phase 2
Recruiting NCT03418961 - S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer Phase 3
Active, not recruiting NCT02993146 - Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases Phase 1
Not yet recruiting NCT06328686 - Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases Early Phase 1
Active, not recruiting NCT02589522 - Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors Phase 1
Recruiting NCT04804644 - Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability Phase 3